Wall Street analysts predict that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will report sales of $699.93 million for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Endo International’s earnings, with estimates ranging from $687.30 million to $715.65 million. Endo International reported sales of $786.89 million during the same quarter last year, which indicates a negative year-over-year growth rate of 11.1%. The company is scheduled to issue its next earnings report before the market opens on Thursday, November 8th.
According to Zacks, analysts expect that Endo International will report full year sales of $2.82 billion for the current fiscal year, with estimates ranging from $2.78 billion to $2.84 billion. For the next financial year, analysts expect that the company will post sales of $2.86 billion, with estimates ranging from $2.73 billion to $3.00 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Wednesday, August 8th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.22. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The company had revenue of $714.70 million for the quarter, compared to analyst estimates of $679.72 million. During the same period in the prior year, the business earned $0.93 earnings per share. Endo International’s quarterly revenue was down 18.4% on a year-over-year basis.
Shares of ENDP stock traded down $0.33 during trading hours on Monday, reaching $16.30. 4,087,788 shares of the company were exchanged, compared to its average volume of 4,522,957. Endo International has a fifty-two week low of $5.27 and a fifty-two week high of $18.50. The firm has a market capitalization of $3.72 billion, a price-to-earnings ratio of 4.24, a PEG ratio of 1.60 and a beta of 0.70.
In related news, Director Roger H. Kimmel sold 26,074 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total transaction of $414,576.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.80% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its stake in shares of Endo International by 13.2% during the second quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock worth $23,074,000 after buying an additional 284,599 shares during the last quarter. New York State Teachers Retirement System raised its stake in shares of Endo International by 27.0% during the second quarter. New York State Teachers Retirement System now owns 356,957 shares of the company’s stock worth $3,366,000 after buying an additional 75,844 shares during the last quarter. Diamond Hill Capital Management Inc. raised its stake in shares of Endo International by 1.0% during the second quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock worth $10,375,000 after buying an additional 10,600 shares during the last quarter. Sivik Global Healthcare LLC bought a new stake in shares of Endo International during the second quarter worth approximately $1,697,000. Finally, Schroder Investment Management Group raised its stake in shares of Endo International by 78.1% during the second quarter. Schroder Investment Management Group now owns 747,571 shares of the company’s stock worth $7,349,000 after buying an additional 327,775 shares during the last quarter. 98.43% of the stock is owned by institutional investors and hedge funds.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Story: How is Preferred Stock Different from Common Stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.